Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients at 2021 American Society of Clinical Oncology Annual Meeting
Survival benefit observed in two treatment settings of previously treated non-small lung cancer patients
June 04, 2021 09:00 ET | Source: Heat Biologics Heat Biologics Morrisville, North Carolina, UNITED STATES
DURHAM, N.C., June 04, 2021 (GLOBE NEWSWIRE) Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Dr. Roger B. Cohen, MD, Professor of Medicine at the University of Pennsylvania Perelman School of Medicine, presented an overview of the latest HS-110 data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting which is being held from June 4-8, 2021. This poster presentation can be viewed on Heat Biologi
Matt York/AP
toggle caption Matt York/AP
Dr. William Burke reviews a PET brain scan at Banner Alzheimer s Institute in Phoenix in 2018. An experimental Alzheimer s drug from Biogen and Eisai is on the verge of a Food and Drug Administration decision. Matt York/AP
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer s disease rather than relieve symptoms.
But it s unclear whether the Food and Drug Administration will approve the drug because of persistent questions about its effectiveness.
The FDA has a Monday deadline to make a decision on what would be the first new Alzheimer s drug in nearly two decades.
Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients at 2021 American Society of Clinical Oncology Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.